Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 4/20 | 0.38 |
| ▸ | NOS1 | P29475 | 4/20 | 0.38 |
| ▸ | NOS2 | P35228 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TERT | O14746 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | NQO1 | P15559 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14108680 | 0.81 | NOS3 (0.39) | NOS3NOS1NOS2LMNAKDM4E | |
| SCHEMBL17298246 | 0.81 | NOS3 (0.38) | NOS3NOS1NOS2KDM4ETERT | |
| SCHEMBL26688044 | 0.77 | KHK (0.36) | LMNA | |
| SCHEMBL9753602 | 0.77 | NOS3 (0.44) | NOS3NOS1NOS2LMNAKDM4E | |
| SCHEMBL28292898 | 0.77 | NOS3 (0.44) | NOS3NOS1NOS2LMNAKDM4E | |
| SCHEMBL27454384 | 0.75 | CYP3A4 (0.43) | NOS3NOS1NOS2LMNAKDM4E | |
| SCHEMBL4480880 | 0.74 | NOS3 (0.37) | NOS3NOS1NOS2KDM4E | |
| SCHEMBL3220307 | 0.73 | NOS3 (0.48) | NOS3NOS1NOS2LMNAKDM4E | |
| Hydrochloric Acid SCHEMBL27496477 | 0.73 | CYP3A4 (0.42) | NOS3NOS1NOS2LMNAKDM4E | |
| SCHEMBL10144932 | 0.71 | NOS3 (0.38) | NOS3NOS1NOS2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653248-B2 | 2-aminopyridine and 2-pyridone C-nucleosides | ISIS PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20030120065-A1 | 2-aminopyridine and 2-pyridone C-nucleosides | ISIS PHARMACEUTICALS, INC. | 2003-06-26 | — | — | US | disclosed |
| US-6495672-B1 | DIAGNOSIS AND SEPARATION THROUGH TRIPLEX BINDING | ISIS PHARMACEUTICALS, INC. | 2002-12-17 | — | — | US | disclosed |
| US-6447998-B1 | METHOD OF DETECTING THE PRESENCE, ABSENCE OR AMOUNT OF A PARTICULAR DNA DUPLEX IN A SAMPLE SUSPECTED OF CONTAINING DNA COMPRISING CONTACTING THE SAMPLE WITH AN OLIGOMER OF UNDER CONDITIONS WHEREIN A TRIPLE HELIX IS FORMED BETWEEN THE | ISIS PHARMACEUTICALS, INC. | 2002-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120065-A1 | 2-aminopyridine and 2-pyridone C-nucleosides | NT5C2, NT5C3B, TYMP | NOS3 4306/4885NOS1 4336/4885NOS2 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.